Table 4.2.
Liposomal medicines in the market
| Encapsulated drug | Trade name | Company | Indication | Approval | Innovator company |
|---|---|---|---|---|---|
| Amphotericin B | Abelcet | Sigma-Tau PharmaSource, Inc., Indianapolis, IN | Severe fungal infections | 1995 | The Liposome Company |
| Amphotericin B | AmBisome | Gilead Sciences, Inc., San Dimas, CA | Severe fungal infections | 1997 | Vestar |
| Amphotericin B | Amphotec | Ben Venue Laboratories, Inc., Bedford, OH | Severe fungal infections | 1996 | Sequus, Pharmaceuticals Inc. |
| Cytarabine | DepoCyt | Enzon/SkyePharma | Lymphomatous meningitis (intrathecal administration) | 1999 | Chiron Corporation and SkyePharma |
| Daunorubicin | DaunoXome | Gilead Sciences, Inc. | Kaposi sarcoma | 1996 | Gilead |
| Doxorubicin | Lipodox (generic of Doxil) | TTY Biopharm Company Ltd., Taipei, Taiwan | Kaposi sarcoma, ovarian/breast cancer | 2013 (FDA approved; USA) | Sun Pharma |
| Doxorubicin | Doxil (USA), Caelyx (Europe) | Essex (Europe) Ortho Biotech (USA) | Breast and ovarian cancer, Kaposi sarcoma | 1995 (conditional) | Sequus Pharmaceuticals, Inc. |
| Doxorubicin | Myocet | Novartis Pharma AG, Basel, Switzerland | Breast cancer | 2000 (EU) | The Liposome Company |
| Irinotecan | Onivyde | Merrimack Pharmaceutical Inc. of Cambridge, Massachusetts | Advanced pancreatic cancer | 2015 (FDA approved; USA) | Merrimack Pharmaceuticals |
| Verteporfin | Visudyne | Novartis Pharma AG, Basel, Switzerland | Age-related molecular degeneration, pathologic myopia, ocular histoplasmosis | 2000 | QLT |
| Vincristine | Marqibo | Spectrum Pharmaceuticals Inc. | Philadelphia chromosome-negative (Ph–) acute lymphoblastic leukemia (ALL) | 2012 (FDA approved; USA) | Inex and Enzon |